Vanguard Global Advisers
SYRE icon

Vanguard Global Advisers’s Spyre Therapeutics SYRE Stock Holding History

Vanguard Global Advisers’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Buy
34,500
+3,359
+11% +$245K ﹤0.01% 1001
2026
Q1 		$1.57M Buy
+31,141
New +$1.17M ﹤0.01% 1359

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Global Advisers's SYRE Position: Q2 2026 in Review

Vanguard Global Advisers increased its Spyre Therapeutics (SYRE) stake by 11% in Q2 2026, buying an estimated $245K and bringing the position to 34,500 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1001.

Vanguard Global Advisers first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Vanguard Global Advisers held 34,500 shares of Spyre Therapeutics worth $3.06M as of Q2 2026.
  • Vanguard Global Advisers bought 3,359 Spyre Therapeutics shares in Q2 2026, an estimated $245K.
  • Spyre Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1001 holding.
  • Vanguard Global Advisers first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.